About
One of the major challenges in the fight against cancer is to find and identify the cancer cells. In this disease, it is our own cells that lose control, so cancer cells look like every other cell in our body and it is challenging to differentiate healthy cells from the diseased cancer cells. All cells are covered with a dense protective sugar-coating. Cancer cells shield themselves with sugar-coat masks to look just like healthy cells, but their sugar-coating is actually slightly different.
Glyconia unlocked the code for identifying cancer cells and killing them specifically, based on their unique sugar-coating, that is different from healthy cells.
Glyconia has a unique platform and multidisciplinary know-how, leading the development of breakthrough CAR-T immunotherapy, targeting the sugar-coating on cancer cells. Glyconia has a proprietary technology that allows targeting cancer cell-surface glycosylation at high efficiency and potency.
Q&A
- What is Glyconia's primary focus?
- Glyconia focuses on developing breakthrough CAR-T immunotherapy solutions for cancer, specifically targeting the unique sugar-coating on cancer cells to differentiate and kill them.
- When was Glyconia founded?
- Glyconia was founded in June 2022.
- What is Glyconia's current operational status?
- Glyconia is currently inactive, having ceased operations in January 2024.
- What is Glyconia's primary sector?
- Glyconia's primary sector is Health Tech & Life Sciences, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- What is the current stage of Glyconia's product development?
- Glyconia's product is in the R&D stage.
- What is Glyconia's current funding stage?
- Glyconia is in the Pre-Funding stage.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/89196836 |
Identifiers & details
| Founded | 2022-6 |
|---|---|
| Status reason | Non Active, Jan 2024 ceased to operate |